Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 26Neoplasms 7Liver Neoplasms 7Leukemia, Myeloid, Acute 6Carcinoma, Renal Cell 5Breast Neoplasms 5Recurrence 3Leukemia 3Kidney Neoplasms 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Melanoma 2Leukemia, Myelomonocytic, Chronic 2Gliosarcoma 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1

Interventions

Gemcitabine 3Capecitabine 3tivozanib 2pembrolizumab 2Oxaliplatin 2Cisplatin 2trametinib 1tislelizumab 1spartalizumab 1silmitasertib 1pertuzumab 1olutasidenib 1devimistat 1atezolizumab 1Sorafenib 1Ritonavir 1Pemetrexed 1Nivolumab 1Itraconazole 1Ipilimumab 1Epirubicin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Bile Duct Neoplasms × Sorafenib × Clear all
NCT00634751 2019-11-26

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

University of Wisconsin, Madison

Phase 1/2 Completed
48 enrolled 13 charts
Gastrointestinal

Bile Duct Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡